Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.65 |
| ▸ | ABL1 | P00519 | 8/20 | 0.65 |
| ▸ | ABL2 | P42684 | 2/20 | 0.65 |
| ▸ | BRAF | P15056 | 3/20 | 0.64 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.64 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.59 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 6/20 | 0.55 |
| ▸ | PRKCA | P17252 | 5/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.55 |
| ▸ | CDK1 | P06493 | 3/20 | 0.53 |
| ▸ | FADS1 | O60427 | 1/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9928275 | 0.84 | EGFR (0.58) | EGFRABL1ABL2BRAFTNNI3K | |
| SCHEMBL12655345 | 0.81 | TTBK1 (0.55) | EGFRABL1ABL2BRAFTNNI3K | |
| SCHEMBL9928278 | 0.81 | EGFR (0.58) | EGFRABL1ABL2BRAFTNNI3K | |
| SCHEMBL7022596 | 0.81 | BRAF (0.60) | EGFRABL1ABL2BRAFTNNI3K | |
| Hydrochloric Acid SCHEMBL7017702 | 0.80 | BRAF (0.59) | EGFRABL1ABL2BRAFTNNI3K | |
| SCHEMBL29406611 | 0.79 | EGFR (1.00) | EGFRABL1ABL2PRKCA | |
| SCHEMBL4935748 | 0.79 | EGFR (0.65) | EGFRABL1ABL2TTBK1TTBK2 | |
| SCHEMBL2463632 | 0.79 | EGFR (1.00) | EGFRABL1ABL2PRKCA | |
| SCHEMBL9943150 | 0.79 | EGFR (0.53) | EGFRABL1ABL2BRAFTNNI3K | |
| SCHEMBL9896825 | 0.79 | JAK3 (0.68) | EGFRABL1ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | BUCK INST RES AGING (US) | 2024-07-04 | — | — | US | disclosed |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | LEXICON PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | LEXICON PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | TNF, IL6, CXCL8 | EGFR 1259/4885ABL1 2163/4885ABL2 2006/4885 |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | DAGLA, DAGLB, MGLL | EGFR 2964/4885ABL1 4054/4885ABL2 4060/4885 |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | CPT1B, CPT1A, SHBG | EGFR 3860/4885ABL1 1600/4885ABL2 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.